Nippon India Pharma Fund-Growth Plan-Growth Option
₹533.2115
₹6.49 (-1.20%)
NAV as of 29 May 2026
Today's NAV — all variants
Regular · Growth
₹₹533.2115
₹6.49 (-1.20%)
29 May 2026
AMFI: 102431
Direct · Growth
₹₹598.5008
₹7.26 (-1.20%)
29 May 2026
AMFI: 118759
Regular · IDCW
₹₹115.1438
₹1.40 (-1.20%)
29 May 2026
AMFI: 102433
Direct · IDCW
₹₹163.7970
₹1.99 (-1.20%)
29 May 2026
AMFI: 118756
Returns (Lumpsum)
CAGR for periods ≥ 1 yearReturns calculated from 25 August 2011 onwards due to a structural change in the scheme on that date. Pre-2011 NAV history is preserved but excluded from multi-year return calculations. Periods spanning this date show —.
SIP Returns (XIRR)
₹1,000/month SIP, annualisedSIP since inception — what ₹500/month became
Real NAV backtest from day one
₹1,31,500
Invested
₹13,99,540
Value today
18.3%
XIRR (p.a.)
₹500/month SIP from fund inception · Current value as of today
Try SIP Calculator with this fund's history₹1,000 lumpsum at launch — value today
Invested on the fund's first NAV date
₹1,000
Invested
₹53,321
Value today
19.8%
CAGR (p.a.)
One-time investment at fund inception · Growth purely from NAV appreciation
Try Lumpsum Calculator₹10L corpus with ₹5,000/month withdrawals since inception
Corpus is still growing despite monthly payouts
₹10,00,000
Initial corpus
₹13,15,000
Withdrawn
₹3,93,25,745
Corpus left
+₹3,96,40,745 net gain — withdrew ₹13,15,000 AND corpus grew
Plan your SWP with real NAV₹6L corpus via 12-month STP from a liquid fund at inception
₹50K/month transferred from HDFC Liquid → this fund at launch
₹6,00,000
Invested
₹2,74,18,844
Value today
-14.3%
vs lumpsum
Direct lumpsum would have beaten STP by 14.3% — but STP reduced timing risk
Model your own STP with real NAVBeat the benchmark — ₹500/month SIP
Same SIP in this fund vs the benchmark index
This fund
₹13,99,540
Benchmark
₹6,85,450
+₹7,14,090 extra wealth vs the benchmark index
Backtest this SIP yourself₹1 lakh on the worst crash day — 22 Mar 2020
Worst single-day Nifty drop during this fund's life
₹1,00,000
Invested
₹4,08,991
Value today
4.1×
Multiple
Staying invested through that crash turned ₹1L into ₹4,08,991 — a 4.1× return
Read: Staying invested through crashesDirect vs Regular — ₹500/month over 10 years
Expense ratio drag on your actual returns
Direct plan
₹1,58,613
Regular plan
₹1,49,826
Direct earns ₹8,787 more on a ₹60K investment — 1.46% extra return per year
Same fund, same NAV history — only the expense ratio differs. Direct plans always outperform Regular over time.
Learn about Direct vs Regular plansFund Details
Risk Metrics
Trailing 1 year, annualised-0.09
Sharpe Ratio
+0.01
Alpha
0.33
Beta
-0.09
Sortino
14.24%
Std Dev
-14.84%
Max Drawdown
Portfolio Holdings
Top 50 holdings · as of Mar 2026
| Security | % NAV |
|---|---|
Sun Pharmaceutical Industries Limited INE044A01036 | 13.92% |
Sun Pharmaceutical Industries Limited INE044A01036 | 13.85% |
Lupin Limited INE326A01037 | 8.45% |
Lupin Limited INE326A01037 | 7.95% |
Dr. Reddy's Laboratories Limited INE089A01031 | 7.04% |
Divi's Laboratories Limited INE361B01024 | 6.61% |
Divi's Laboratories Limited INE361B01024 | 6.41% |
Dr. Reddy's Laboratories Limited INE089A01031 | 5.96% |
Cipla Limited INE059A01026 | 5.47% |
Cipla Limited INE059A01026 | 5.42% |
Apollo Hospitals Enterprise Limited INE437A01024 | 5.15% |
Apollo Hospitals Enterprise Limited INE437A01024 | 5.01% |
MedPlus Health Services Limited INE804L01022 | 3.86% |
MedPlus Health Services Limited INE804L01022 | 3.78% |
Ajanta Pharma Limited INE031B01049 | 3.36% |
Vijaya Diagnostic Centre Limited INE043W01024 | 3.36% |
Sai Life Sciences Limited INE570L01029 | 3.27% |
Max Healthcare Institute Limited INE027H01010 | 3.24% |
Ajanta Pharma Limited INE031B01049 | 3.19% |
Max Healthcare Institute Limited INE027H01010 | 3.16% |
Sai Life Sciences Limited INE570L01029 | 3.15% |
Vijaya Diagnostic Centre Limited INE043W01024 | 3.15% |
Mankind Pharma Limited INE634S01028 | 3.04% |
Mankind Pharma Limited INE634S01028 | 2.87% |
Aurobindo Pharma Limited INE406A01037 | 2.83% |
Aurobindo Pharma Limited INE406A01037 | 2.81% |
IPCA Laboratories Limited INE571A01038 | 2.77% |
GlaxoSmithKline Pharmaceuticals Limited INE159A01016 | 2.64% |
GlaxoSmithKline Pharmaceuticals Limited INE159A01016 | 2.55% |
IPCA Laboratories Limited INE571A01038 | 2.50% |
Abbott India Limited INE358A01014 | 2.43% |
Abbott India Limited INE358A01014 | 2.26% |
Alkem Laboratories Limited INE540L01014 | 2.17% |
Thyrocare Technologies Limited INE594H01019 | 2.11% |
Alkem Laboratories Limited INE540L01014 | 2.09% |
JB Chemicals & Pharmaceuticals Limited INE572A01036 | 2.09% |
Dr. Lal Path Labs Limited INE600L01024 | 2.02% |
Dr. Lal Path Labs Limited INE600L01024 | 1.99% |
Thyrocare Technologies Limited INE594H01019 | 1.94% |
Pfizer Limited INE182A01018 | 1.90% |
Pfizer Limited INE182A01018 | 1.79% |
Narayana Hrudayalaya Limited INE410P01011 | 1.74% |
Gland Pharma Limited INE068V01023 | 1.72% |
Gland Pharma Limited INE068V01023 | 1.68% |
Narayana Hrudayalaya Limited INE410P01011 | 1.67% |
Emcure Pharmaceuticals Limited INE168P01015 | 1.51% |
Emcure Pharmaceuticals Limited INE168P01015 | 1.50% |
Syngene International Limited INE398R01022 | 1.43% |
Suraksha Diagnostic Limited INE877V01027 | 1.32% |
Fortis Healthcare Limited INE061F01013 | 1.22% |
Performance Comparison
Interested in This Fund?
Our experts will help you decide if this fund fits your goals.
Compare with Similar Funds
Investment Objective
Nippon India Pharma Fund-Growth Plan-Growth Option invests in stocks from a specific sector or theme, offering concentrated exposure to a particular area of the economy. These funds carry sector-specific risks but can deliver significant returns when the underlying sector performs well.
About This Fund
Nippon India Pharma Fund-Growth Plan-Growth Option is a Sectoral / Thematic mutual fund offered by Nippon India Mutual Fund. The fund has been operational for over 21 years. It manages assets worth ₹8,116 Cr, reflecting investor confidence in the fund's strategy. It benchmarks its performance against BSE HEALTHCARE TRI. The current expense ratio is 1.81%.
Who Should Invest?
- •Investors with a high risk appetite seeking long-term wealth creation
- •Investors with an investment horizon of 5 years or more
- •SIP investors who can benefit from rupee cost averaging during market fluctuations